Brand Names: Farxiga

Dapagliflozin is an SGLT2 inhibitor that works by blocking a particular protein that causes the kidney to reabsorb glucose. When blocked, excess glucose is eliminated through the urine. This medication was approved by the U.S. FDA in January 2014 for patients with type 2 diabetes in conjunction with diet and exercise.

Fatigue, rapid weight loss, frequent urination, urinary tract infections, and thrush.

Community Rating: 3.0

Rate and Review